奥泰生物
(688606)
| 流通市值：51.33亿 | | | 总市值：51.33亿 |
| 流通股本：7928.09万 | | | 总股本：7928.09万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 208,475,751.58 | 866,582,952.58 | 618,025,472.14 | 396,503,367.26 |
| 营业收入 | 208,475,751.58 | 866,582,952.58 | 618,025,472.14 | 396,503,367.26 |
| 二、营业总成本 | 143,277,319.88 | 571,937,182.55 | 425,103,891.99 | 272,928,388.15 |
| 营业成本 | 92,500,751.86 | 383,743,801.78 | 273,429,699.73 | 178,394,130.3 |
| 税金及附加 | 2,933,860.99 | 9,565,171.69 | 4,774,025.45 | 3,578,736.62 |
| 销售费用 | 14,008,023.23 | 55,388,921.47 | 41,885,987.45 | 30,047,771.37 |
| 管理费用 | 15,047,510.18 | 64,841,632.7 | 45,636,701.66 | 30,135,503.89 |
| 研发费用 | 21,152,185.22 | 95,824,901.05 | 71,504,941.41 | 49,158,799.28 |
| 财务费用 | -2,365,011.6 | -37,427,246.14 | -12,127,463.71 | -18,386,553.31 |
| 其中:利息费用 | 55,903.58 | 415,350.86 | 366,181.49 | 260,841.93 |
| 其中:利息收入 | 2,271,240.09 | 33,468,165.72 | 17,858,437.69 | 17,477,200.31 |
| 加:公允价值变动收益 | 2,101,122.21 | 35,548,454.9 | 22,550,628.77 | 12,656,702.03 |
| 加:投资收益 | 517,478.78 | 12,194,620.55 | 11,590,830.28 | 9,206,166.83 |
| 资产处置收益 | - | 1,224,694.32 | 3,480,365.44 | 3,342,244.85 |
| 资产减值损失(新) | -100,097.18 | -9,071,584.44 | -7,314,634.97 | -8,386,371.65 |
| 信用减值损失(新) | -4,499,759.64 | -7,790,927.99 | -13,940,234.76 | -12,262,428 |
| 其他收益 | 1,357,605.08 | 18,766,875.51 | 17,493,941.76 | 13,918,354.85 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 64,574,780.95 | 345,517,902.88 | 226,782,476.67 | 142,049,648.02 |
| 加:营业外收入 | - | 3,186,384.61 | 179,812.1 | 179,742.51 |
| 减:营业外支出 | 54,959.48 | 990,907.36 | 3,644,577.57 | 3,080,758.59 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 64,519,821.47 | 347,713,380.13 | 223,317,711.2 | 139,148,631.94 |
| 减:所得税费用 | 3,340,800.48 | 44,803,527.41 | 25,772,550.07 | 15,614,052.2 |
| 六、净利润 | 61,179,020.99 | 302,909,852.72 | 197,545,161.13 | 123,534,579.74 |
| 持续经营净利润 | 61,179,020.99 | 302,909,852.72 | 197,545,161.13 | 123,534,579.74 |
| 归属于母公司股东的净利润 | 61,216,292.5 | 302,471,981.38 | 197,526,404.8 | 123,879,409.14 |
| 少数股东损益 | -37,271.51 | 437,871.34 | 18,756.33 | -344,829.4 |
| (一)基本每股收益 | 0.77 | 3.82 | 2.49 | 1.56 |
| (二)稀释每股收益 | 0.77 | 3.82 | 2.49 | 1.56 |
| 八、其他综合收益 | -276,672.56 | 1,762,140.42 | -1,478,128.56 | 648,531.96 |
| 归属于母公司股东的其他综合收益 | -274,164.54 | 1,745,866.01 | -1,478,414.22 | 637,986.09 |
| 九、综合收益总额 | 60,902,348.43 | 304,671,993.14 | 196,067,032.57 | 124,183,111.7 |
| 归属于母公司股东的综合收益总额 | 60,942,127.96 | 304,217,847.39 | 196,047,990.58 | 124,517,395.23 |
| 归属于少数股东的综合收益总额 | -39,779.53 | 454,145.75 | 19,041.99 | -334,283.53 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |